China Hinye Pharmaceutical Co. Ltd. has identified pyrrole sulfonyl compounds and deuterated derivatives acting as H+/K+-ATPase inhibitors reported to be useful for the treatment of peptic ulcers, Zollinger-Ellison syndrome, gastroesophageal reflux disease, dyspepsia, reflux esophagitis, Barrett esophagus, Helicobacter pylori infection and gastric cancer.
Microbiome specialist Enterobiotix Ltd. has reported positive results for the phase Ib trial of its EBX-102 fecal microbiota therapy in patients with stable liver cirrhosis. The placebo-controlled study involved first-in-human dosing with the company’s encapsulated oral formulation of microbiota derived from the stools of healthy donors. After initial dosing, patients were followed up for 12 weeks to assess changes in a range of clinical and blood biomarkers.
OSE Therapeutics SA has reported positive data for lusvertikimab in a phase II trial in ulcerative colitis, boosting the monoclonal antibody’s prospects of becoming the first anti-interleukin-7 therapy to reach the market.
Werewolf Therapeutics Inc. has expanded its pipeline with the addition of a novel IL-10 Indukine development candidate, WTX-921, for inflammatory bowel disease (IBD) and potentially other inflammatory diseases.
Liver diseases are responsible for around two million deaths every year. Among them, hepatocellular carcinoma (HCC), particularly at late stages, presents limited therapeutic options and a dismal survival rate.
Suzhou Ansailong Pharmaceutical Technology Co Ltd. has identified mitochondrial ATP-dependent Clp protease proteolytic subunit (ClpP) activators reported to be useful for the treatment of cancer, AIDS, nonalcoholic fatty liver disease (metabolic dysfunction-associated steatotic liver disease [MASLD]) and neurological disorders.
Rectify Pharmaceuticals Inc. has nominated the positive functional modulator (PFM) RTY-694 as a development candidate for primary sclerosing cholangitis (PSC). As the lead PFM in Rectify’s hepatobiliary program, RTY-694 is now advancing to first-in-human trials for PSC.
According to World Health Organization data, endometriosis affects about 10% of reproductive-age females globally. That already makes endometriosis a wildly underresearched and underfunded disease in relation to its prevalence. Plus, Rama Kommagani thinks even 10% is an underestimation.
Researchers from Phoenixlab, The Scripps Research Institute and affiliated organizations presented the discovery of a novel bivalent protease-activated receptor PAR1- and PAR3-derived peptide, named biparetide, being developed for the treatment of inflammatory bowel disease (IBD).
In what represents the first patenting from Cerathrive Ltd., its co-founder and CEO, Sarah Turner, describes their development of the Cera system, which they claim to be the first and only U.S. FDA-cleared red-light device that targets the gut-brain axis to improve focus and energy levels.
RSS
